Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA™ round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result. The NATRELLE INSPIRA™ line of breast implants is designed for women who are interested in increased breast fullness. NATRELLE INSPIRA™ breast implants are fuller than Allergan's round, gel-filled breast implants currently available in the U.S.

"NATRELLE INSPIRA™ is just the latest example of our commitment to breast aesthetics and plastic surgery which will continue into the future," said Philippe Schaison, President, Allergan Medical.

The FDA approval of NATRELLE INSPIRA™ round gel-filled textured breast implants marks the most recent addition to the broad portfolio of currently available NATRELLE^® products in the U.S. The smooth version of the NATRELLE INSPIRA™ round gel-filled breast implants was approved by FDA in February 2015.

"NATRELLE INSPIRA™ round gel-filled breast implants have been available in Canada since 2011 and are of particular interest to women seeking to gain breast fullness following pregnancy or undergoing revision or reconstruction surgery," said Dr. Paul Whidden of MacLeod Trail Plastic Surgery. "Although there are many breast implant options available today, my patients continue to request the combination of fullness and softness NATRELLE INSPIRA™ breast implants can provide them."